• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Reed-Lane

    Emergent BioSolutions

    Adare Pharma Solutions

    Flow Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Emergent BioSolutions

    Adare Pharma Solutions

    Flow Sciences

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CEO Spotlight: Will Downie

    Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO

    CEO Spotlight: Will Downie
    Vectura's CEO Will Downie talks with Contract Pharma
    Tim Wright, Editor, Contract Pharma04.01.20
    Vectura is a UK-based pharmaceuticals business that provides product formulation and development services for inhaled pharmaceuticals as well as developing devices to deliver drugs across dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs), and smart nebulizers.

    The company employs more than 400 people at its Chippenham, UK headquarters, and at its other UK sites in Cambridge and London, as well as in Switzerland and Germany.

    Vectura has a rich heritage as an inhalation product development company, and in 2019 announced that it was to become a leading player in the inhalation segment of the contract development and manufacturing organization (CDMO) market, offering formulation and development services to companies ranging from small innovator biotechs to large pharma.

    Contract Pharma had the chance to sit down with Vectura’s Chief Executive Officer, Will Downie, who joined Vectura in November 2019, to talk about how the company has aligned its services with the needs of the development market, and the current nature of the inhaled-drug market.

    Contract Pharma (CP): What was the strategy behind changing from a development company into a CDMO service provider?

    Will Downie:
    Over the course of the last twenty years, Vectura has leveraged its inhaled drug development and inhalation device capabilities to establish a number of strong partnerships with pharmaceutical companies. Since 2012, our formulation and device technology has contributed to the success of 11 inhaled medicines, launched by our partners and licensees, generating $10 billion in sales. In 2018 these products were used by 9 million patients worldwide.

    Our business model to date has been to co-invest in the development of products with our clients, making money through a series of milestones and royalties; as well as developing our own products. We will no longer be doing the latter and we will focus solely on being a CDMO service provider, as well as working with our current partners.

    The rationale behind this is that we can use our deep scientific knowhow and world-class technology to move more robustly into the outsourcing space and diversify our customer base. We hold an enviable position, having deep expertise in both pharmaceuticals and delivery devices, so the focus will remain within this field, but working with a wider number of molecules and across a broader range of disease states.


    On the inside of one of Vectura's lab spaces.

    CP: What is the current state of the inhaled drug industry, and the pipeline of new products coming through?

    Downie:
    The market is very buoyant and growing. Industry data reveals that there are over 300 molecules1 within the drug development pipeline today that require an inhaled route of delivery. For Vectura, with the expertise we can offer, there is real interest in about 70% of these molecules which sit in the pre-clinical to phase II stages and likely need some assistance and development work to make them commercially-viable products.

    It is important to note that the molecules currently in development are not limited to respiratory diseases such as asthma and COPD. There are a number of opportunities for delivery of drugs through the lungs for therapies targeting indications from CNS and endocrinology disorders, to oncology and pulmonary vascular diseases.

    We know that the CDMO market as a whole is growing and corresponding outsourcing rates are increasing, especially for smaller innovator companies where the outsourcing rates are particularly high, as their business model is almost entirely virtual. With this increase in outsourcing, there is a continued need for innovation, as companies look to differentiate their products and meet payor demands. What we see as a real opportunity for Vectura is that the drive for innovation is opening up the route of inhalation delivery of products to be broader than just respiratory medicine, and there is a need for both the optimization of complex combination drug products and the development of complex generics going forward.

    CP:  What are the current trends within the industry, and what challenges does it face? How is Vectura looking to address these?

    Downie: 
    In the broad healthcare environment, we are seeing a number of trends which touch upon our part of the industry. Firstly, digital health is becoming prevalent on the high street, and the combination of smart devices and pharmaceuticals will continue to become even more important in the future. We can also see that personalized medicine has at last become a reality, and product development is now being undertaken to treat smaller sub-populations of patients, orphan disease states, and in some cases, even individual patients. Finally—and this is by no means a new phenomenon—looking at all the development pipelines of biopharmaceutical companies, there is a steady increase in the number of large molecules coming to market and being developed.


    One of Vectura's Dry Powder Inhalers.
    The challenges in drug development are well documented, and as molecules become more complex, issues around bioavailability and solubility need to be overcome. This is not unique to inhaled drugs, but the science around inhaled product development and device technology is very challenging, and the barrier to entry in the market as a service provider is very high.

    As a company, we work with customers at any stage of their drug development cycle after drug discovery, all the way from pre-clinical formulation stage to late stage commercial scale up. By partnering with customers with early development molecules, we can help them to optimize their chances of success as they move through clinical trial development. During the development process we can also utilize our device technology expertise to create the optimal delivery platform for the drug product, with patient compatibility and compliance in mind at all times.

    The experience we have, with over two decades of formulation and device technology development, is a massive advantage in overcoming the current challenges, and the eleven products launched to date bear testament to this. Looking forward, we foresee that the drivers in the inhaled drug arena will be to meet the need for effective particle engineering and formulation of large, as well as complex small, molecules. In addition, ensuring devices deliver drugs in ways that allow for the growing focus of patient centricity and increased adherence to be met. There is a current digital drive to combine devices with smart phones and apps so that dosages can be tracked and accurately prescribed, and there is a need to adapt nebulizers in the future in order to become “smart” and deliver product to the lungs more effectively. Additionally, the industry needs to look at current dry powder inhalers and find ways to increase their deliverable payloads.

    Vectura has always had the philosophy of developing simple devices to overcome complex challenges, and provide excellent compatibility for patients and increasing probability of success for our customers.

    CP: What are the future plans for Vectura and what especially excites you about your relatively new role?

    Downie: 
    Our ultimate mission at Vectura is to improve the lives of patients who can benefit from the successful delivery of medicines through an inhaled route of administration.
    The switch to being a CDMO will allow us to demonstrate our expertise in a much broader inhalation market and move away from our more historical narrow product development focus. The change in focus will see us continuing to invest in areas where we can differentiate our capabilities and technologies against competitors, but will as a consequence diversify our customer base.

    The heart of our company lies in the world-class expertise of our scientific and engineering staff, who are adept at working across the spectrum of pharmaceutical development and device technology. Having the expertise in both offers simplicity for clients and allows us to forge true partnerships throughout a product’s lifecycle.

    The ability to combine drug development and device technology is rare in the marketplace today. Our expertise in helping clients with formulation and device solutions, together with connected digitization, can unlock the potential of our clients’ product challenges. 

    Sources
    1. Global Data pipeline analysis (July 2019) – “Respiratory” includes infectious disease assets Small & medium-sized respiratory companies excludes companies with significant in-house inhalation capabilities: Astra Zeneca, GSK, Bayer, Novartis, BI, Pfizer, Chiesi, Orion 1 Contract development and manufacturing organization.


    Will Downie was appointed Chief Executive Officer of Vectura in November 2019. Prior to joining Vectura, Will spent ten years as the senior vice president, global sales and marketing at Catalent. In this role, he led the commercial effort and had responsbility for global sales, marketing and commercial operations activities. During his tenure, he developed an outstanding track record in helpin drive the long-term growth of the company, as well as positioning Catalent as one of the leading brands in the pharmaceutical services space.
    Related Searches
    • Phase II
    • chief executive officer
    • bioavailability
    • novartis

    Related Features

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20

    • Drug Delivery
      Wet Wipes Increased Prevalence in Drug Development

      Wet Wipes Increased Prevalence in Drug Development

      A number of factors including patient preference are driving the growth of wet wipes in pharma.
      John Waddell, Business Development Director – Pharma, PDI Contract Manufacturing 10.14.20

    • Drug Delivery
      Not Your Father’s Oral Thin Film

      Not Your Father’s Oral Thin Film

      A look at how oral film drug delivery is evolving.
      Rodolphe Obeid, Vice President of Operations, IntelGenx 06.04.20


    • Drug Delivery | Regulatory Affairs
      Regulatory Overhaul for Medical Devices

      Regulatory Overhaul for Medical Devices

      Implications for the pharmaceutical industry.
      Elizma Parry, Director, Global Clinical Practice, Maetrics 06.04.20

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Delivery
      Nasal Drug Delivery

      Nasal Drug Delivery

      A look at best practices for testing nasal drug delivery devices
      Maria Smith, senior manager & Charles Shaw, scientific advisor, Renaissance Lakewood LLC 01.25.19


    • Drug Delivery | Drug Development
      Traveling Toward the Intersection of Drug Development and Delivery

      Traveling Toward the Intersection of Drug Development and Delivery

      Overcoming the challenges of delivering drugs to patients.
      Louise Righton, Global Marketing Operations Manager, 3M Drug Delivery Systems 06.12.18

    • Drug Delivery | Solid Dosage/Creams/Ointments
      FDCs on the Rise

      FDCs on the Rise

      Fixed-dose combination drugs continue to gain traction due to a multitude of benefits they offer, including speed to market a
      Betsy Louda, Associate Editor, Contract Pharma 03.09.18

    • Drug Delivery
      The Future of Inhaled Medications and Inhalation Technology

      The Future of Inhaled Medications and Inhalation Technology

      Formulations, devices and strategy through non-clinical development
      Simon Moore, Envigo 10.11.17


    • Drug Delivery
      Digital Drug Delivery: A Snapshot in Time

      Digital Drug Delivery: A Snapshot in Time

      Technology is transforming the future of drug delivery
      Sam Van Alstyne, 3M Drug Delivery Systems 10.11.17

    • Drug Delivery | Drug Development
      Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect

      Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect

      The challenges of using the lung as a portal for the treatment of systemic conditions
      Tugrul Kararli, Kurt Sedo, Josef Bossart, PHARMACIRCLE 10.11.16

    • Aseptic Processing | Biosimilars | Drug Delivery | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16


    • Biosimilars | Drug Delivery | Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16

    • Drug Delivery | Drug Development | Excipients | Process Development | Process Validation | Risk Management | Validation
      Process Development Trends

      Process Development Trends

      An approach to process development of pMDIs using cold fill and pressure fill technology
      Steve Haswell, 3M Drug Delivery Systems 05.05.16

    • Aseptic Processing | Biosimilars | cGMP Manufacture | Drug Delivery | Injectables | Parenterals
      Injectables: The New Oral?

      Injectables: The New Oral?

      The growth trend of injectables continues across the pharma landscape.
      Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC 04.05.16

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    P&G, L'Oréal & Amorepacific Make News at CES
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login